Cargando…

Defining TP53 pioneering capabilities with competitive nucleosome binding assays

Accurate gene expression requires the targeting of transcription factors (TFs) to regulatory sequences often occluded within nucleosomes. The ability to target a TF binding site (TFBS) within a nucleosome has been the defining characteristic for a special class of TFs known as pioneer factors. Recen...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Xinyang, Buck, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314159/
https://www.ncbi.nlm.nih.gov/pubmed/30409772
http://dx.doi.org/10.1101/gr.234104.117
_version_ 1783384076974030848
author Yu, Xinyang
Buck, Michael J.
author_facet Yu, Xinyang
Buck, Michael J.
author_sort Yu, Xinyang
collection PubMed
description Accurate gene expression requires the targeting of transcription factors (TFs) to regulatory sequences often occluded within nucleosomes. The ability to target a TF binding site (TFBS) within a nucleosome has been the defining characteristic for a special class of TFs known as pioneer factors. Recent studies suggest TP53 functions as a pioneer factor that can target its TFBS within nucleosomes, but it remains unclear how TP53 binds to nucleosomal DNA. To comprehensively examine TP53 nucleosome binding, we competitively bound TP53 to multiple in vitro–formed nucleosomes containing a high- or low-affinity TP53 TFBS located at differing translational and rotational positions within the nucleosome. Stable TP53–nucleosome complexes were isolated and quantified using next-generation sequencing. Our results demonstrate TP53 binding is limited to nucleosome edges with significant binding inhibition occurring within 50 bp of the nucleosome dyad. Binding site affinity only affects TP53 binding for TFBSs located at the same nucleosomal positions; otherwise, nucleosome position takes precedence. Furthermore, TP53 has strong nonspecific nucleosome binding facilitating its interaction with chromatin. Our in vitro findings were confirmed by examining TP53-induced binding in a cell line model, showing induced binding at nucleosome edges flanked by a nucleosome-free region. Overall, our results suggest that the pioneering capabilities of TP53 are driven by nonspecific nucleosome binding with specific binding at nucleosome edges.
format Online
Article
Text
id pubmed-6314159
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Cold Spring Harbor Laboratory Press
record_format MEDLINE/PubMed
spelling pubmed-63141592019-07-01 Defining TP53 pioneering capabilities with competitive nucleosome binding assays Yu, Xinyang Buck, Michael J. Genome Res Method Accurate gene expression requires the targeting of transcription factors (TFs) to regulatory sequences often occluded within nucleosomes. The ability to target a TF binding site (TFBS) within a nucleosome has been the defining characteristic for a special class of TFs known as pioneer factors. Recent studies suggest TP53 functions as a pioneer factor that can target its TFBS within nucleosomes, but it remains unclear how TP53 binds to nucleosomal DNA. To comprehensively examine TP53 nucleosome binding, we competitively bound TP53 to multiple in vitro–formed nucleosomes containing a high- or low-affinity TP53 TFBS located at differing translational and rotational positions within the nucleosome. Stable TP53–nucleosome complexes were isolated and quantified using next-generation sequencing. Our results demonstrate TP53 binding is limited to nucleosome edges with significant binding inhibition occurring within 50 bp of the nucleosome dyad. Binding site affinity only affects TP53 binding for TFBSs located at the same nucleosomal positions; otherwise, nucleosome position takes precedence. Furthermore, TP53 has strong nonspecific nucleosome binding facilitating its interaction with chromatin. Our in vitro findings were confirmed by examining TP53-induced binding in a cell line model, showing induced binding at nucleosome edges flanked by a nucleosome-free region. Overall, our results suggest that the pioneering capabilities of TP53 are driven by nonspecific nucleosome binding with specific binding at nucleosome edges. Cold Spring Harbor Laboratory Press 2019-01 /pmc/articles/PMC6314159/ /pubmed/30409772 http://dx.doi.org/10.1101/gr.234104.117 Text en © 2019 Yu and Buck; Published by Cold Spring Harbor Laboratory Press http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see http://genome.cshlp.org/site/misc/terms.xhtml). After six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Method
Yu, Xinyang
Buck, Michael J.
Defining TP53 pioneering capabilities with competitive nucleosome binding assays
title Defining TP53 pioneering capabilities with competitive nucleosome binding assays
title_full Defining TP53 pioneering capabilities with competitive nucleosome binding assays
title_fullStr Defining TP53 pioneering capabilities with competitive nucleosome binding assays
title_full_unstemmed Defining TP53 pioneering capabilities with competitive nucleosome binding assays
title_short Defining TP53 pioneering capabilities with competitive nucleosome binding assays
title_sort defining tp53 pioneering capabilities with competitive nucleosome binding assays
topic Method
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314159/
https://www.ncbi.nlm.nih.gov/pubmed/30409772
http://dx.doi.org/10.1101/gr.234104.117
work_keys_str_mv AT yuxinyang definingtp53pioneeringcapabilitieswithcompetitivenucleosomebindingassays
AT buckmichaelj definingtp53pioneeringcapabilitieswithcompetitivenucleosomebindingassays